Boston Scientific warns it will miss 2026 forecasts after cyberattack disrupts global operations
Boston Scientific announced on September 8, 2026, that a cybersecurity incident first detected on August 25 disrupted its global manufacturing, order processing, and shipments, making it unlikely to meet its third-quarter and full-year 2026 sales and adjusted profit forecasts. The company had forecast 2026 adjusted earnings of $3.28 to $3.32 per share and net sales growth of 5.5% to 6.5%. Shares fell over 4% to $45.73. Recovery is underway, but the full financial impact remains uncertain.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Common ground
- Both agree that the Boston Scientific cyberattack is not just an IT problem but a patient safety and supply chain crisis.
- Both agree that the lack of mandatory cybersecurity standards for medical device manufacturing is a critical regulatory gap.
- Both agree that the company's vague public statements are a problem, though they differ on the reasons for the silence.
- Both agree that the market's 5% stock drop reflects some level of risk pricing, but they interpret its significance differently.
Points of contention
- Western Agent argues the market is normalizing catastrophic risk, while Neutral Agent says the drop is a rational response to a temporary disruption.
- Western Agent believes Boston Scientific's silence is a cover-up to protect liability, while Neutral Agent argues it's a tactical necessity during ransom negotiations.
- Western Agent holds that board members should face consequences for the attack, while Neutral Agent focuses on the need for regulatory reform over individual accountability.
- Western Agent sees the 'everyone gets hacked' argument as a dangerous excuse, while Neutral Agent views it as a statistical reality that shifts focus to recovery capability.
Blind spots
- Neither side fully addressed the supply chain concentration risk—how a single factory shutdown can halt global shipments of critical, single-source medical devices.
- Both overlooked the possibility that the cyberattack may be a convenient scapegoat for pre-existing business problems, like the underperformance of Boston Scientific's Watchman device.
- The debate missed the role of Congress in failing to fund and empower the FDA to enforce cybersecurity standards for manufacturing lines.
WorldAttention’s read
This debate shows that the Boston Scientific hack is a symptom of a deeper problem: we treat medical device manufacturing as a regular business, not the critical national infrastructure it is. Both sides agree that cybersecurity can't be voluntary anymore—it must be a mandatory safety requirement. The real fix isn't blaming one company or its board; it's closing the regulatory gap that lets factories operate without enforceable security standards. Until Congress gives the FDA the power and money to oversee these systems, patients will keep paying the price for attacks that should have been preventable.
Reporting timeline
Boston Scientific Misses 2026 Guidance After Cyberattack Disrupts Operations
Boston Scientific warned on September 8, 2026, that it will likely miss its full-year and third-quarter net sales growth and adjusted earnings per share guidance due to a cyberattack that disrupted manufacturing and order fulfillment globally. The company first detected unauthorized activity on its IT systems on August 25, causing a network outage that blocked access to operating systems and business applications. Boston Scientific stock fell over 4% to $45.73. The company had previously projected full-year adjusted earnings of $3.28 to $3.32 per share and net sales growth of 5.5% to 6.5%. Recovery is underway, with logistics infrastructure largely back online and manufacturing resumed at most facilities, but the total financial impact remains undetermined. The situation draws comparisons to a March attack on rival Stryker. J.P. Morgan analysts noted structural disadvantages for Boston Scientific, including a portfolio weighted toward single-use consumables, making lost sales largely unrecoverable, and limited time left in the year to make up ground. This warning compounds a difficult year for the company, which had already reduced its profit and sales outlook in late July due to underperformance of its Watchman heart implant. Boston Scientific stock has fallen roughly 50% in 2026.
Read sourceBoston Scientific: Cybersecurity incident disrupts product shipments, will miss annual forecasts
Boston Scientific, a major medical device manufacturer, announced that a cybersecurity incident has disrupted its ability to ship products to customers. The company stated that this operational disruption will cause it to miss its financial forecasts for the current year. The announcement was made via the company's official social media account, indicating a significant impact on its supply chain and revenue projections. The specific nature of the cybersecurity incident, including whether it involved ransomware, data theft, or other malicious activity, has not been detailed in this initial statement. The incident highlights the growing vulnerability of critical healthcare infrastructure and manufacturing operations to cyber threats, with direct consequences for patient care and corporate financial performance. Boston Scientific's stock and investor sentiment are likely to be affected by this news as the market assesses the duration and full cost of the disruption.
Read sourceBoston Scientific says unlikely to meet 2026 sales, profit forecast after cyberattack
Boston Scientific announced on September 8, 2026, that it no longer expects to meet its previously issued third-quarter and full-year 2026 sales and adjusted profit forecasts due to a cybersecurity incident. The unauthorized activity on its IT systems, first identified on August 25, caused a network outage that disrupted manufacturing, order processing, and shipments globally. The company had forecast 2026 adjusted earnings of $3.28 to $3.32 per share and net sales growth of 5.5% to 6.5%. For Q3, it expected adjusted earnings of 80 to 82 cents per share. Boston Scientific has made progress restoring systems, with major distribution centers now processing orders at normal levels and manufacturing resumed at most facilities. It expects to recover some lost revenue but the full financial impact remains uncertain. Shares fell 2.1% in premarket trading. The incident is part of a series of cyberattacks on the healthcare sector, including recent attacks on Abbott Laboratories, Stryker, Medtronic, Clover Health, and Novo Nordisk. Boston Scientific will provide an update when it reports Q3 results on October 28.
Read sourceShow 2 older updatesHide older updates
Boston Scientific says unlikely to meet 2026 sales, profit forecast after cyberattack
Boston Scientific announced on September 8, 2026, that it no longer expects to meet its previously issued third-quarter and full-year 2026 sales and adjusted profit forecasts due to a cybersecurity incident that disrupted its global operations. The company first identified unauthorized activity on some of its information technology systems on August 25, causing a network outage that affected access to operating systems and business applications, disrupting manufacturing and the processing and shipment of customer orders. Boston Scientific had forecast 2026 adjusted earnings of $3.28 to $3.32 per share and net sales growth between 5.5% and 6.5%. For the third quarter, it expected adjusted earnings of 80 to 82 cents per share. The company has made progress restoring affected systems, with major distribution centers now processing and shipping orders at or above normal levels, sterilization facilities operational, and manufacturing resumed across most facilities globally. Boston Scientific expects to recover a portion of lost revenue as it ramps up operations and reduces backlogs, but the full financial impact remains uncertain. The incident is the latest in a series of cyberattacks on the healthcare sector, including recent attacks on Abbott Laboratories, Stryker, Medtronic, Clover Health, and Novo Nordisk. The company plans to provide an update when it reports third-quarter results on October 28.
Boston Scientific warns it will miss financial guidance after cyberattack disrupts operations
Boston Scientific announced that it is unlikely to meet its financial guidance due to a cyberattack that has disrupted its operations. The medical-technology company's shares fell sharply in premarket trading following the announcement. The cyberattack has impacted the company's ability to operate normally, leading to the revised financial outlook. The incident highlights the growing vulnerability of healthcare and technology companies to cyber threats, which can have immediate and significant financial repercussions. Boston Scientific has not provided details on the nature of the attack or when it expects operations to fully resume. Investors reacted negatively to the news, driving the stock price down in early trading. The company is expected to provide further updates as it assesses the full impact of the cyberattack on its business and financial performance.
Read source